Home > In process > Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations. > print

001     284366
005     20260130153117.0
024 7 _ |a 10.1007/s00702-025-02911-5
|2 doi
024 7 _ |a pmid:40121314
|2 pmid
024 7 _ |a 0375-9245
|2 ISSN
024 7 _ |a 0022-3026
|2 ISSN
024 7 _ |a 0300-9564
|2 ISSN
024 7 _ |a 1435-1463
|2 ISSN
037 _ _ |a DZNE-2026-00134
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Koeglsperger, Thomas
|0 P:(DE-2719)2810825
|b 0
|e First author
|u dzne
245 _ _ |a Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.
260 _ _ |a Wien [u.a.]
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769783246_7436
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Traditional advanced therapies in Parkinson's disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI's advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Advanced Treatment
|2 Other
650 _ 7 |a Foslevodopa/Foscarbidopa
|2 Other
650 _ 7 |a Motor Fluctuations
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Antiparkinson Agents
|2 NLM Chemicals
650 _ 7 |a Levodopa
|0 46627O600J
|2 NLM Chemicals
650 _ 7 |a Carbidopa
|0 MNX7R8C5VO
|2 NLM Chemicals
650 _ 7 |a Drug Combinations
|2 NLM Chemicals
650 _ 7 |a carbidopa, levodopa drug combination
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Antiparkinson Agents: administration & dosage
|2 MeSH
650 _ 2 |a Antiparkinson Agents: adverse effects
|2 MeSH
650 _ 2 |a Levodopa: administration & dosage
|2 MeSH
650 _ 2 |a Levodopa: adverse effects
|2 MeSH
650 _ 2 |a Carbidopa: administration & dosage
|2 MeSH
650 _ 2 |a Carbidopa: adverse effects
|2 MeSH
650 _ 2 |a Drug Combinations
|2 MeSH
650 _ 2 |a Infusions, Subcutaneous
|2 MeSH
700 1 _ |a Berberovic, Emir
|b 1
700 1 _ |a Dresel, Christian
|b 2
700 1 _ |a Haferkamp, Sebastian
|b 3
700 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 4
|u dzne
700 1 _ |a Müller, Rahel
|b 5
700 1 _ |a Oehlwein, Christian
|b 6
700 1 _ |a Paus, Sebastian
|b 7
700 1 _ |a Urban, Peter Paul
|b 8
773 _ _ |a 10.1007/s00702-025-02911-5
|g Vol. 133, no. 2, p. 347 - 359
|0 PERI:(DE-600)1481655-6
|n 2
|p 347 - 359
|t Journal of neural transmission
|v 133
|y 2026
|x 0375-9245
856 4 _ |u https://pub.dzne.de/record/284366/files/DZNE-2026-00134.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/284366/files/DZNE-2026-00134.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810825
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001967
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURAL TRANSM : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21